Translating cellular therapies from bench to bedside for amyotrophic lateral sclerosis

Personalized Medicine

Volumn 9, Issue 6, 2012, Pages 645-655

  Riley, Jonathan ^a   Hurtig, Carl V ^a   Boulis, Nicholas ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

amyotrophic lateral sclerosis; intraspinal microinjection; spinal cord; stem cell therapy; targeted delivery

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; IMMUNOSUPPRESSIVE AGENT;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CELL SURVIVAL; CELL THERAPY; CELL VIABILITY; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DRUG DELIVERY SYSTEM; ENDOPLASMIC RETICULUM; FOLLOW UP; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MICROINJECTION; MOTONEURON; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; THERAPY EFFECT;

EID: 84865495092     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.74     Document Type: Article

References (59)

1. Feldman EL. Amyotrophic lateral sclerosis and other motor neuron diseases. In: Cecil Textbook of Medicine. WB Saunders, Philadelphia, PA, USA, 2316-2319 (2004
2. Xu L, Yan J, Chen D et al. Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation 82(7), 865-875 (2006 (Pubitemid 44564030)
3. Yan J, Xu L, Welsh AM et al. Extensive neuronal differentiation of human neural stem cell grafts in adult rat spinal cord. PLoS Med. 4(2), e39 (2007
4. Xu L, Ryugo DK, Pongstaporn T, Johe K, Koliatsos VE. Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: Differentiation and structural integration into the segmental motor circuitry. J. Comp. Neurol. 514(4), 297-309 (2009
5. Suzuki M, Mchugh J, Tork C et al. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE 2(8), e689 (2007
6. Riley J, Federici T, Polak M et al. Intraspinal stem cell transplantation in ALS: A Phase I safety trial, technical note and lumbar safety outcomes. Neurosurgery 71(2), 405-416 (2012
7. Riley JP, Raore B, Taub JS, Federici T, Boulis NM. Platform and cannula design improvements for spinal cord therapeutics delivery. Neurosurgery 69(2 Suppl. Operative), ons147-ons154; discussion ons155 (2011
8. Liu J, Lillo C, Jonsson PA et al. Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron 43(1), 5-17 (2004 (Pubitemid 38952815)
9. Vande Velde C, Miller TM, Cashman NR, Cleveland DW. Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc. Natl Acad. Sci. USA 105(10), 4022-4027 (2008). (Pubitemid 351723517)
10. Kikuchi H, Almer G, Yamashita S et al. Spinal cord endoplasmic reticulum stress associated with a microsomal accumulation of mutant superoxide dismutase-1 in an ALS model. Proc. Natl Acad. Sci. USA 103(15), 6025-6030 (2006
11. Nishitoh H, Kadowaki H, Nagai A et al. ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev. 22(11), 1451-1464 (2008 (Pubitemid 351793080)
12. Kabashi E, Agar JN, Taylor DM, Minotti S, Durham HD. Focal dysfunction of the proteasome: A pathogenic factor in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 89(6), 1325-1335 (2004 (Pubitemid 38802654)
13. Cheroni C, Marino M, Tortarolo M et al. Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis. Hum. Mol. Genet. 18(1), 82-96 (2009
14. Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 187(6), 761-772 (2009
15. Murakami T, Nagano I, Hayashi T et al. Impaired retrograde axonal transport of adenovirus-mediated E. coli LacZ gene in the mice carrying mutant SOD1 gene. Neurosci. Lett. 308(3), 149-152 (2001 (Pubitemid 32710146)
16. Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat. Neurosci. 2(1), 50-56 (1999 (Pubitemid 30488940)
17. Perlson E, Jeong GB, Ross JL et al. A switch in retrograde signaling from survival to stress in rapid-onset neurodegeneration. J. Neurosci. 29(31), 9903-9917 (2009
18. Usvald D, Vodicka P, Hlucilova J et al. Analysis of dosing regimen and reproducibility of intraspinal grafting of human spinal stem cells in immunosuppressed minipigs. Cell Transplant. 19(9), 1103-1122 (2010
19. Yang Y, Gozen O, Watkins A et al. Presynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1. Neuron 61(6), 880-894 (2009
20. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 38(1), 73-84 (1995
21. Bruijn LI, Becher MW, Lee MK et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18(2), 327-338 (1997 (Pubitemid 27111114)
22. Howland DS, Liu J, She Y et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS)Proc. Natl Acad. Sci. USA 99(3), 1604-1609 (2002 (Pubitemid 34136539)
23. Harraz MM, Marden JJ, Zhou W et al. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J. Clin. Invest. 118(2), 659-670 (2008 (Pubitemid 351206555)
24. Zhao W, Beers DR, Henkel JS et al. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 58(2), 231-243 (2010
25. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 65(Suppl. 1), S3-S9 (2009
26. Maragakis NJ, Rao MS, Llado J et al. Glial restricted precursors protect against chronic glutamate neurotoxicity of motor neurons in vitro. Glia 50(2), 145-159 (2005 (Pubitemid 40695268)
27. Park S, Kim HT, Yun S et al. Growth factor-expressing human neural progenitor cell grafts protect motor neurons but do not ameliorate motor performance and survival in ALS mice. Exp. Mol. Med. 41(7), 487-500 (2009
28. Henderson CE, Phillips HS, Pollock RA et al. GDNF: A potent survival factor for motoneurons present in peripheral nerve and muscle. Science 266(5187), 1062-1064 (1994 (Pubitemid 24373728)
29. Boucherie C, Schafer S, Lavand'homme P, Maloteaux JM, Hermans E. Chimerization of astroglial population in the lumbar spinal cord after mesenchymal stem cell transplantation prolongs survival in a rat model of amyotrophic lateral sclerosis. J. Neurosci. Res. 87(9), 2034-2046 (2009
30. Lepore AC, Rauck B, Dejea C et al. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci. 11(11), 1294-1301 (2008
31. Yan J, Xu L, Welsh AM et al. Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in amyotrophic lateral sclerosis transgenic mice. Stem Cells 24(8), 1976-1985 (2006 (Pubitemid 44474174)
32. Xu L, Ryugo DK, Pongstaporn T, Johe K, Koliatsos VE. Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry. J. Comp. Neurol. 514(4), 297-309 (2009
33. Lindvall O, Björklund A. Cell therapy in Parkinson's disease. NeuroRx 1(4), 382-393 (2004 (Pubitemid 46589366)
34. Federici T, Boulis NM. Gene therapy for amyotrophic lateral sclerosis. Neurobiol. Dis. doi:10.1016/j.nbd.2011.08.018 (2011) (Epub ahead of print
35. Riley J, Federici T, Park J et al. Cervical spinal cord therapeutics delivery: preclinical safety validation of a stabilized microinjection platform. Neurosurgery 65(4), 754-761; discussion 761-752 (2009
36. Riley J, Butler J, Baker KB et al. Targeted spinal cord therapeutics delivery: stabilized platform and microelectrode recording guidance validation. Stereotac. Funct. Neurosurg. 86(2), 67-74 (2008 (Pubitemid 351341531)
37. Raore B, Federici T, Taub J et al. Cervical multilevel intraspinal stem cell therapy. assessment of surgical risks in Gottingen minipigs. Spine 36(3), e164-e171 (2011
38. Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G. New paradigm in dose-finding trials: patient-specific dosing and beyond Phase I. Clin. Cancer Res. 11, 5342-5346 (2005 (Pubitemid 41060806)
39. Reiner E, Paoletti X, O'Quigley J. Operating characteristics of the standard Phase I clinical trial design. Comput. Stat. Data Anal. 30(3), 303-315 (1999
40. Glass JD, Boulis NM, Johe K et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis. results of a Phase I trial in 12 patients. Stem Cells 30(6), 1144-1151 (2012
41. Mazzini L, Mareschi K, Ferrero I et al. Stem cell treatment in amyotrophic lateral sclerosis. J. Neurol. Sci. 265(1-2), 78-83 (2008
42. Mazzini L, Ferrero I, Luparello V et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis. A Phase I clinical trial. Exp. Neurol. 223(1), 229-237 (2010
43. Chen L, Chen D, Xi H et al. Olfactory ensheathing cell neurorestorotherapy for amyotrophic lateral sclerosis patients: benefits from multiple transplantations. Cell Transplant. 21(Suppl. 1), S65-S77 (2012
44. Corti S, Locatelli F, Donadoni C et al. Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. Brain 127(Pt 11), 2518-2532 (2004 (Pubitemid 39472980)
45. Vercelli A, Mereuta OM, Garbossa D et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 31(3), 395-405 (2008).
46. Mazzini L, Fagioli F, Boccaletti R. Stem-cell therapy in amyotrophic lateral sclerosis. Lancet 364(9449), 1936-1937 (2004 (Pubitemid 39574591)
47. Mazzini L, Fagioli F, Boccaletti R et al. Stem cell therapy in amyotrophic lateral sclerosis: A methodological approach in humans. Amyotroph. Lateral. Scler. Other Motor Neuron Disord. 4(3), 158-161 (2003 (Pubitemid 37184884)
48. Blanquer M, Perez Espejo MA, Iniesta F et al. [Bone marrow stem cell transplantation in amyotrophic lateral sclerosis. technical aspects and preliminary results from a clinical trial]. Methods Find. Exp. Clin. Pharmacol. 32(Suppl. A), 31-37 (2010
49. Chen L, Chen D, Xi H et al. Olfactory ensheathing cell neurorestorotherapy for amyotrophic lateral sclerosis patients. Benefits from multiple transplantations. Cell Transplant. 21(Suppl. 1), S65-S77 (2012
50. Giordana MT, Grifoni S, Votta B et al. Neuropathology of olfactory ensheathing cell transplantation into the brain of two amyotrophic lateral sclerosis (ALS) patients. Brain Pathol. 20(4), 730-737 (2010
51. Knoller N, Auerbach G, Fulga V et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: Phase I study results. J. Neurosurg. Spine 3(3), 173-181 (2005
52. Huang H, Chen L, Wang H et al. Safety of fetal olfactory ensheathing cell transplantation in patients with chronic spinal cord injury. A 38 month follow-up with MRI. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 20(4), 439-443 (2006
53. Mazzini L, Mareschi K, Ferrero I et al. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis. a long-term safety study. Cytotherapy 14(1), 56-60 (2012
54. Huang H, Chen L, Wang H et al. Influence of patients' age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury. Chin. Med. J. (Engl.) 116(10), 1488-1491 (2003 (Pubitemid 37461660)
55. Chen L, Huang H, Zhang J et al. Short-term outcome of olfactory ensheathing cells transplantation for treatment of amyotrophic lateral sclerosis. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 21(9), 961-966 (2007
56. Feron F, Perry C, Cochrane J et al. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain 128(Pt 12), 2951-2960 (2005 (Pubitemid 41746648)
57. Deda H, Inci MC, Kurekci AE et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: A 1 year follow-up. Cytotherapy 11(1), 18-25 (2009
58. Yoon SH, Shim YS, Park YH et al. Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: Phase I/II clinical trial. Stem Cells 25(8), 2066-2073 (2007
59. Blanquer M, Moraleda JM, Iniesta F et al. Neurotrophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: A pilot safety study. Stem Cells 30(6), 1277-1285 (2012).